论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
纳米级 MTCA-KKV:用于靶向血栓,释放药效团,抑制血栓形成和溶解体内血栓
Authors Zhao S, Li Z, Huang F, Wu J, Gui L, Zhang X, Wang Y, Wang X, Peng S, Zhao M
Received 21 February 2019
Accepted for publication 23 May 2019
Published 3 July 2019 Volume 2019:14 Pages 4817—4831
DOI https://doi.org/10.2147/IJN.S206294
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Melinda Thomas
Peer reviewer comments 2
Editor who approved publication: Dr Linlin Sun
Background: In vitro (1R,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val (MTCA-KKV) adheres activated platelets, targets P-selectin and GPIIb/IIIa. This led to the development of MTCA-KKV as thrombus targeting nano-medicine.
Methods: MTCA-KKV was characterized by nano-feature, anti-thrombotic activity, thrombolytic activity, thrombus target and targeting release.
Results: In vivo 0.01 μmol/kg of MTCA-KKV formed nano-particles less than 100 nm in diameter, targeted thrombus, released anti-thrombotic and thrombolytic pharmacophores, prevented thrombosis and dissolved blood clots.
Conclusion: Based on the profiles of targeting thrombus, targeting release, inhibiting thrombosis and dissolving blood clots MTCA-KKV is a promising nano-medicine.
Keywords: nano-particles, anti-thrombotic, thrombolytic, targeting, release